Syndax Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the …

Biotechnology
US, Waltham [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of SNDX's Analysis
CIK: 1395937 CUSIP: 87164F105 ISIN: US87164F1057 LEI: - UEI: -
Secondary Listings
SNDX has no secondary listings inside our databases.